查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830070

肺炎链球菌疫苗市场（按疫苗类型、年龄层、分销管道和最终用户划分）—2025-2032 年全球预测

Pneumococcal Vaccine Market by Vaccine Type, Age Group, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年肺炎球菌疫苗市场将成长至 216.7 亿美元，复合年增长率为 8.16%。

主要市场统计数据
基准年2024年 115.6亿美元
预计2025年 124.9亿美元
预测年份：2032年 216.7亿美元
复合年增长率（%） 8.16%

构成当代肺炎链球菌疫苗接种优先事项和实施要务的最新临床和政策进展的策略方向

肺炎链球菌疫苗领域正处于蓬勃发展的科学进步与不断变化的公共卫生重点的交汇点。结合疫苗製剂的最新进展、成人和老年人群疫苗许可范围的扩大以及对预防侵袭性肺炎球菌疾病的重新关注，正在再形成临床指南和疫苗接种途径。同时，监管机构不断完善针对高风险族群的建议和季节性疫苗接种策略，促使医疗保健提供者和免疫接种计画重新评估其疫苗接种政策和营运工作流程。

这些动态包括改进疫苗配方以扩大血清型覆盖范围，并透过优化供应链和医疗服务提供者教育，策略性地推动提高公平可及性。同时，製造商、公共卫生机构和临床协会之间也加强了合作，以确保适应症、给药方案和上市后监测的一致性。因此，从采购到临床点的相关人员正在重新调整临床方案和供应结构，以反映疫苗交付的科学进步和物流现实。

决策者必须清楚了解最新的临床数据、政策更新和交付限制。整合这些要素有助于制定协调一致的策略，以设计疫苗接种计划、制定处方决策并涵盖高风险族群，确保临床效益转化为可衡量的公共卫生影响。

产品创新、监管调整和供应链现代化如何重新定义肺炎链球菌疫苗供应和临床决策

在产品创新、监管调整和供应基础日趋成熟的推动下，肺炎链球菌疫苗生态系统正经历转型变革。新型结合剂型能够扩大血清型覆盖范围，正在改变临床决策，并为前几代疫苗未能充分覆盖的成年人和老年人提供更广泛的保护。这一演变强化了从依赖单一产品向多样化选择的转变，临床医生和付款人必须根据临床效益、操作可行性和成本效益进行评估。

同时，监管和咨询委员会的指导方针正在根据新出现的证据进行调整，这为免疫接种计画带来了机会和营运挑战。製造商正在采取以证据为导向的核准后生命週期策略，并与卫生部门合作，以确保扩大附加檔覆盖范围。同时，分销网络和低温运输物流也日益复杂，整合了数位视觉化工具和区域伙伴关係关係，以减少浪费并扩大对服务匮乏地区的覆盖范围。

总体而言，这种转变促使相关人员优先考虑敏捷采购、强化监测以及针对医疗保健提供者的有针对性的教育。透过使供应策略与临床指导一致，卫生系统可以在能够最大程度地提高公共卫生效益的领域促进疫苗接种，同时管理更广泛的产品组合和不断变化的疫苗接种计划所带来的物流复杂性。

评估贸易政策变化和关税调整对疫苗供应链、采购弹性和交付连续性的下游营运影响

近年来，为调整关税制度和贸易状况而出台的政策措施正在对支持疫苗生产和分销的医药和医疗供应链产生实际影响。进口关税的变化以及医疗投入审查通讯协定和实践的变化可能会影响零件、低温运输设备和辅助用品的成本基础，进而影响公共和私人免疫项目的筹资策略。当关税波动导致关键投入品在岸采购成本增加时，製造商和经销商通常会采取应对措施，例如优化采购、与供应商协商长期合约以及加快对本地製造能力的投资。

对于肺炎球菌疫苗而言，关税调整的累积影响需要仔细审查涵盖原始抗原采购、管瓶和注射器供应商以及温控物流供应商的供应链。医疗保健机构和製造商越来越希望实现供应多元化和在岸化，以降低进口相关成本波动带来的风险。同时，采购负责人也更加重视能够锁定供应承诺并明确海关相关延误责任的合约条款。

因此，参与疫苗供应的组织正在重新评估其采购框架、低温运输容量预算假设以及应急计划，以确保疫苗接种服务的连续性。这些调整凸显了综合供应链风险管理的重要性，该管理应将贸易政策动态以及临床和营运方面的考虑纳入考虑。

一个细分主导的框架，将疫苗类型区分、年龄优先、分销管道和护理环境与营运和临床决策联繫起来。

细緻的细分视角清楚地阐明了产品属性、患者人口统计、通路和护理环境如何影响需求模式和专案优先顺序。疫苗类型分为结合疫苗和多醣体疫苗，结合疫苗中又包含特定剂型，例如PCV13、PCV15和PCV20。根据年龄组，针对成人、儿童和老年族群量身订做临床和计画策略，同时考虑到易感性、併发症情况和建议给药方案的差异。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 将新型20价肺炎链球菌结合疫苗快速纳入国家免疫规划
  • 扩大公私合营，改善医疗资源匮乏地区的疫苗接种服务
  • 扩大对基于mRNA的肺炎球菌疫苗平台的投资，以加速开发
  • 非疫苗血清型的出现导致流行病学发生变化，推动了下一代製剂的发展
  • 监理机关加速核准加速新型肺炎链球菌疫苗的上市

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 肺炎链球菌疫苗市场（依疫苗类型）

  • 结合疫苗
    • PCV13
    • PCV15
    • PCV20
  • 多醣体疫苗

9. 肺炎链球菌疫苗市场（依年龄层）

  • 成人
  • 孩子
  • 老年人

第 10 章肺炎链球菌疫苗市场（按分销管道）

  • 离线
  • 在线的

第 11 章。肺炎链球菌疫苗市场（按最终用户）

  • 门诊治疗中心
  • 诊所
  • 医院
  • 疫苗接种中心

12. 肺炎链球菌疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 肺炎链球菌疫苗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按国家/地区分類的肺炎链球菌疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AstraZeneca PLC
    • Biological E. Limited
    • Biovac
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Incepta Pharmaceuticals Ltd.
    • Lonza AG
    • Merck & Co., Inc.
    • Panacea Biotec Limited
    • Pfizer, Inc.
    • Sanofi SA
    • Serum Institute of India Pvt. Ltd.
    • Vaxcyte Inc.
    • Walvax Biotechnology Co., Ltd.
Product Code: MRR-43539E5D3200

The Pneumococcal Vaccine Market is projected to grow by USD 21.67 billion at a CAGR of 8.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.56 billion
Estimated Year [2025] USD 12.49 billion
Forecast Year [2032] USD 21.67 billion
CAGR (%) 8.16%

A strategic orientation to recent clinical and policy advances that frame contemporary pneumococcal vaccination priorities and implementation imperatives

The pneumococcal vaccine landscape sits at the intersection of robust scientific advancement and evolving public health priorities. Recent developments in conjugate vaccine formulations, expanded licensure across adult and geriatric populations, and a renewed emphasis on preventing invasive pneumococcal disease have reshaped clinical guidelines and vaccination pathways. At the same time, regulatory bodies continue to refine recommendations for high-risk groups and seasonal immunization strategies, prompting healthcare providers and immunization programs to revisit coverage policies and operational workflows.

Across clinical and operational domains, two parallel dynamics are evident: the refinement of vaccine composition to broaden serotype coverage and a strategic push to improve equitable access through supply chain optimization and provider education. These dynamics are accompanied by intensified collaboration among manufacturers, public health agencies, and clinical societies to ensure alignment on indications, administration schedules, and post-marketing surveillance. As a result, stakeholders from procurement to point-of-care are recalibrating clinical protocols and supply arrangements to reflect both the scientific advances and the logistical realities of vaccine delivery.

For decision-makers, a clear understanding of recent clinical data, policy updates, and delivery constraints is essential. Integrating these elements supports coherent strategies for immunization program design, formulary decisions, and outreach to populations with elevated risk, thereby ensuring that clinical gains translate into measurable public health impact.

How product innovation, regulatory adaptation, and supply chain modernization are collectively redefining pneumococcal vaccine delivery and clinical decision-making

The pneumococcal vaccine ecosystem is undergoing transformative shifts driven by product innovation, regulatory recalibration, and the maturation of delivery infrastructures. Newer conjugate formulations expanding serotype coverage have altered clinical decision-making, facilitating broader protection for adults and older populations previously underserved by earlier vaccine generations. This evolution is reinforcing a transition from single-product reliance toward a diversified set of options that clinicians and payers must evaluate on the basis of clinical benefit, operational feasibility, and cost-effectiveness.

Meanwhile, regulatory pathways and advisory committee guidance are adapting to emerging evidence, creating both opportunities and operational challenges for immunization programs. Manufacturers are responding with lifecycle strategies that emphasize post-approval evidence and engagement with health authorities to secure label expansions. At the same time, distribution networks and cold chain logistics are becoming more sophisticated, integrating digital visibility tools and regional partnerships to reduce wastage and improve reach into under-immunized communities.

These shifts collectively encourage stakeholders to prioritize agile procurement, enhanced surveillance, and targeted provider education. By aligning supply strategies with clinical guidance, health systems can accelerate uptake where the public health benefit is greatest while managing the logistical complexity introduced by a broader product mix and evolving immunization schedules.

Assessing the downstream operational consequences of altered trade policies and tariff adjustments on vaccine supply chains, procurement resilience, and delivery continuity

Policy measures enacted in recent years to adjust tariff regimes and trade posture have had tangible implications for the pharmaceutical and medical supply chains that support vaccine production and distribution. Changes to import duties, review protocols for medical inputs, and enforcement practices can influence the cost base for components, cold chain equipment, and ancillary supplies, which in turn affects procurement strategies for public and private immunization programs. Where tariff shifts increase landed costs for critical inputs, manufacturers and distributors often respond by optimizing sourcing, negotiating longer-term supplier agreements, and accelerating investments in local manufacturing capabilities.

In the context of pneumococcal vaccines, the cumulative effect of tariff adjustments necessitates careful scrutiny of supply chains that span raw antigen procurement, vial and syringe suppliers, and temperature-controlled logistics providers. Health systems and manufacturers are increasingly focusing on supply diversification and onshoring initiatives to mitigate exposure to import-related cost volatility. Concurrently, procurement officers are placing greater emphasis on contractual terms that lock in supply commitments and clarify responsibility for customs-related delays.

As a result, organizations involved in vaccine delivery are revising procurement frameworks, budgeting assumptions for cold chain capacity, and contingency planning to ensure continuity of vaccination services. These adaptations underscore the importance of integrated supply chain risk management that accounts for trade policy dynamics alongside clinical and operational considerations.

A segmentation-driven framework linking vaccine type differentiation, age-specific priorities, distribution channels, and care settings to operational and clinical decision-making

A nuanced segmentation lens clarifies how product characteristics, patient demographics, distribution pathways, and care settings shape demand patterns and program priorities. Based on Vaccine Type, the landscape is evaluated across Conjugate Vaccine and Polysaccharide Vaccine, with conjugate options further differentiated by specific formulations including Pcv13, Pcv15, and Pcv20; these distinctions influence clinical recommendations, immunogenicity expectations, and cold chain handling requirements. Based on Age Group, clinical and program strategies are tailored for Adult, Children, and Geriatric cohorts given differences in susceptibility, comorbidity profiles, and recommended administration schedules.

Based on Distribution Channel, distribution dynamics vary between Offline and Online pathways, with traditional provider-administered channels remaining central to routine immunization while digital procurement and telehealth-enabled coordination are expanding access and convenience. Based on End User, program design and logistics are shaped by site-specific needs across Ambulatory Care Centers, Clinics, Hospitals, and Immunization Centers, each of which has distinct staffing models, cold storage capacity, and patient throughput patterns. Integrating these segmentation dimensions enables stakeholders to align product selection, education efforts, and logistics investments with the practical realities of each setting and population cohort.

This segmentation-driven approach facilitates targeted interventions, such as prioritizing high-valency conjugate formulations in settings serving older adults or optimizing online ordering workflows for smaller clinics, thereby improving alignment between clinical value and operational delivery.

Regional dynamics and tailored deployment strategies that reconcile diverse healthcare infrastructures, policy landscapes, and delivery priorities across major global regions

Regional dynamics continue to shape how pneumococcal vaccines are introduced, prioritized, and financed across diverse healthcare ecosystems. In the Americas, vaccination programs often balance strong public immunization infrastructure with varied payer arrangements and concentrated efforts to reach marginalized populations. Regional procurement strategies, national immunization schedules, and public health campaigns influence both uptake and program design, prompting collaboration between manufacturers and health authorities to address coverage gaps.

In Europe, Middle East & Africa, the environment is heterogeneous, with high-income health systems focusing on guideline alignment and adult immunization, while low- and middle-income settings prioritize pediatric access and cold chain expansion. Policy heterogeneity across this combined region underscores the need for adaptive distribution strategies and targeted support for regulatory harmonization and capacity building. In the Asia-Pacific region, rapid urbanization, expanding private healthcare delivery, and substantial investments in domestic manufacturing capacity are reshaping access models. Regional stakeholders are leveraging technology-enabled ordering, decentralized cold chain solutions, and partnerships to increase reach in both urban and rural settings.

Across these regions, manufacturers and public health entities must calibrate launch strategies, supply allocation, and educational outreach to reflect local regulatory processes, healthcare delivery models, and population health priorities. Such regional tailoring increases the effectiveness of immunization efforts and facilitates more efficient use of available resources.

Strategic manufacturer initiatives focusing on higher-valency formulations, manufacturing resilience, and evidence-generation to sustain clinical and commercial relevance

The competitive landscape in the pneumococcal vaccine field is characterized by a mix of legacy products and next-generation formulations, with companies focusing on lifecycle management, label expansions, and post-marketing evidence generation to sustain clinical relevance. Strategic priorities among leading manufacturers include advancing higher-valency conjugate options, strengthening regulatory dossiers for adult indications, and expanding manufacturing footprint to enhance supply reliability. Partnerships with contract manufacturers and investments in fill-and-finish capacity are common tactics to accelerate market readiness and reduce bottlenecks associated with sterile manufacturing.

In parallel, manufacturers are investing in real-world evidence programs and pharmacovigilance initiatives to support clinicians and payers in assessing comparative effectiveness and safety across populations. Engagement with advisory bodies and professional societies is central to shaping guideline updates and bolstering clinician confidence in new formulations. Commercial strategies increasingly emphasize value-based propositions that link clinical benefits with operational advantages such as reduced dosing complexity or improved stability at standard refrigeration temperatures.

For purchasers and health systems, understanding each company's manufacturing resilience, evidence-generation plans, and distribution partnerships is essential when assessing supply options. This insight helps inform procurement discussions, risk-sharing arrangements, and collaborative initiatives to expand access while maintaining consistent delivery performance.

Actionable measures for integrating clinical value with supply resilience, stakeholder engagement, and targeted access strategies to enhance vaccine program effectiveness

Industry leaders should prioritize a coherent set of actions that align clinical value, supply resilience, and equitable access. First, integrate product portfolio decisions with operational capabilities by ensuring that procurement strategies reflect differences in formulation requirements, cold chain needs, and administration schedules. This alignment reduces operational friction and supports consistent delivery across diverse care settings. Next, invest in collaborative supply agreements and capacity-building initiatives that reduce exposure to import-related volatility and strengthen regional fill-and-finish capabilities to support timely availability.

Additionally, elevate evidence synthesis and provider engagement efforts to accelerate appropriate uptake. Real-world safety and effectiveness data should be systematically collected and translated into concise clinical tools and decision aids for frontline clinicians. Strengthening partnerships with public health agencies and professional societies will facilitate guideline alignment and improve the clarity of risk-based recommendations. From a commercial perspective, consider structured contracting approaches that include performance clauses and supply continuity commitments, which can mitigate disruption risk and align incentives across stakeholders.

Finally, develop targeted outreach strategies for populations with lower uptake, leveraging digital platforms for appointment scheduling and vaccine reminders while reinforcing in-person access through community immunization centers. These combined steps will help organizations convert scientific advances into measurable improvements in population protection and program efficiency.

A mixed-methods research approach synthesizing clinical evidence, expert input, and operational review to produce actionable and validated insights for stakeholders

The research methodology underpinning this analysis combines systematic literature appraisal, targeted expert interviews, and supply chain review to ensure a robust and transparent evidence base. Peer-reviewed clinical studies, regulatory guidance documents, and publicly available safety surveillance reports formed the foundation for assessing clinical efficacy, indications, and post-authorization experience. Expert input was obtained from clinicians, vaccinologists, supply chain specialists, and health policy advisors to contextualize how evidence translates into operational and procurement decisions across care settings.

Operational insights were developed through examination of distribution channel dynamics, cold chain infrastructure reports, and procurement practice analyses, complemented by engagement with logistics providers and vaccination program managers to validate practical constraints and feasible solutions. Regulatory timelines and label expansions were reviewed to understand how product availability and indication alignment influence clinical practice. Where appropriate, triangulation of data sources and cross-validation with subject matter experts were used to resolve discrepancies and ensure analytical rigor.

This mixed-methods approach balances empirical evidence with practitioner expertise, producing actionable insights that reflect both scientific validity and the pragmatic realities of vaccine delivery and program implementation.

Integrated conclusions linking scientific advancement, regulatory evolution, and operational resilience to practical recommendations for advancing immunization outcomes

In summary, the pneumococcal vaccine environment is advancing along multiple dimensions: scientific innovation in conjugate formulations, evolving policy and guideline landscapes, and a growing emphasis on supply chain robustness. These forces are prompting stakeholders to rethink product selection, procurement strategies, and delivery models to ensure that clinical advances translate into expanded protection across age groups and care settings. Effective responses require integrated planning that spans regulatory engagement, manufacturing resilience, and targeted outreach to populations at elevated risk.

Moving from insight to action involves aligning evidence-generation with operational execution. Strengthened surveillance and real-world data programs, combined with strategic contracting and local capacity investments, can mitigate disruption risk and enhance access. At the clinical interface, continued education and clear guideline communication will be essential to harmonize practice patterns and optimize vaccine utilization across adult, pediatric, and geriatric populations. Ultimately, stakeholders that proactively coordinate clinical, commercial, and logistical strategies will be best positioned to convert recent innovations into sustained public health benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid integration of novel 20-valent pneumococcal conjugate vaccine in national immunization programs
  • 5.2. Expansion of public private partnerships to improve vaccine access in underserved regions
  • 5.3. Growing investment in mRNA based pneumococcal vaccine platforms for faster development
  • 5.4. Shifting epidemiology with emergence of non vaccine serotypes driving next generation formulations
  • 5.5. Regulatory accelerated approval pathways facilitating faster market entry for novel pneumococcal vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccine
    • 8.1.1. Pcv13
    • 8.1.2. Pcv15
    • 8.1.3. Pcv20
  • 8.2. Polysaccharide Vaccine

9. Pneumococcal Vaccine Market, by Age Group

  • 9.1. Adult
  • 9.2. Children
  • 9.3. Geriatric

10. Pneumococcal Vaccine Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Pneumococcal Vaccine Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Immunization Centers

12. Pneumococcal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pneumococcal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pneumococcal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AstraZeneca PLC
    • 15.3.2. Biological E. Limited
    • 15.3.3. Biovac
    • 15.3.4. F. Hoffmann-La Roche AG
    • 15.3.5. GlaxoSmithKline plc
    • 15.3.6. Incepta Pharmaceuticals Ltd.
    • 15.3.7. Lonza AG
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Panacea Biotec Limited
    • 15.3.10. Pfizer, Inc.
    • 15.3.11. Sanofi SA
    • 15.3.12. Serum Institute of India Pvt. Ltd.
    • 15.3.13. Vaxcyte Inc.
    • 15.3.14. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 205. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 216. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 217. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 241. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 252. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 253. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 264. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 265. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 287. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 297. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 306. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 307. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 326. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 327. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 336. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 337. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 338. FRANCE PNEUMOC